-
Agonist Antibodies: Why CD40, OX40 & 4-1BB Need FcγR Crosslinking(Page)
Microglial Functions Explained: Immunity, Inflammation & Neurodegeneration(Post)
Neuroscience · NeuroimmunologyMicroglial Functions: Immunity, Inflammation & NeurodegenerationMicroglia are the resident immune cells of the central nervous system — dynamic sentinels that survey the
Utomilumab: Advancing Immuno-Oncology Research(Post)Quick Facts About UtomilumabWhat is Utomilumab?Utomilumab is a monoclonal antibody targeting 4-1BB (CD137), a co-stimulatory receptor on T-cells, designed to enhance anti-tumor immunity.
Dual PD-1/PD-L2 Blockade: Expanding the Horizons of Cancer Immunotherapy(Post)Introduction to PD-1, PD-L1, and PD-L2 in Cancer ImmunotherapyThe PD-1/PD-L1 immune checkpoint pathway has been instrumental in cancer immunotherapy, with PD-1 (programmed death-1) inhibi
Do Not Eat Me Is Not a Switch(Post)Phagocytosis is a subtraction, not a switch. A macrophage engulfs when its activating signals exceed its inhibitory ones, and every awkward result in the myeloid checkpoint field falls out of that on
Angiotensin Pathways: Unlocking the Secrets to Blood Pressure Regulation and Beyond(Post)The angiotensin pathway is a pivotal hormonal system that plays a crucial role in regulating blood pressure and maintaining fluid and electrolyte balance within the body. This complex biochemical
Patritumab Deruxtecan: Mechanism, Clinical Applications, and Biosimilar Advances(Post)Quick Facts About Patritumab DeruxtecanWhat is Patritumab Deruxtecan?Patritumab Deruxtecan (HER3-DXd) is an investigational antibody-drug conjugate (ADC) targeting HER3, a receptor impli
Necrosis: Types, Causes, Symptoms & Prevention Guide(Post)Cell Biology · PathologyNecrosis: Types, Causes, Mechanisms and How It Is MeasuredNecrosis is cell death accompanied by membrane rupture and release of intracellular contents — which is what makes it
Monalizumab: A Breakthrough in Cancer Immunotherapy Targeting NKG2A(Post)Quick Facts About MonalizumabWhat is Monalizumab?Monalizumab is a first-in-class immune checkpoint inhibitor targeting NKG2A, developed to enhance anti-tumor immune response by blocking
How Furin and ACE2 Interact with the Spike on SARS-CoV-2(Post)What is the Coronavirus Spike Protein? COVID-19, the newest coronavirus to gain international attention, is caused by severe acute respirator
Vixarelimab: A Novel Approach to Targeting Prurigo Nodularis and Fibrosis(Post)Quick Facts About VixarelimabWhat is Vixarelimab?Vixarelimab is an investigational monoclonal antibody developed to target oncostatin M receptor beta (OSMRβ), a key pathway involved in p
Myeloid Checkpoints: CD47-SIRPa, LILRB and Siglec-10(Page) Diabetic Nephropathy & Diabetic Mellitus(Post)Overview of Diabetes Mellitus Diabetes mellitus (DM) is a major epidemic that affects over 347 million people worldwide (Danaei et al. 2011). The World Hea
NK cell activation & innate cytotoxicity(Page) What is pharmacogenomics? (Post)What is pharmacogenomics Pharmacogenomics is how DNA variation and drugs interact and how this can optimise patient health; this involves studying pharmacokinetics and pharmacodynamics.
The Role of Zonulin In Intestinal Permeability (Post)Gastroenterology · Barrier BiologyZonulin and Intestinal PermeabilityZonulin is the best-characterised endogenous regulator of intestinal tight junctions — the protein that opens the gut barrier on de
Etigilimab: Unveiling the Role of Anti-TIGIT in Cancer Research(Post)Key Facts About EtigilimabWhat is Etigilimab?Etigilimab is an anti-TIGIT monoclonal antibody being studied for its potential role in cancer immunotherapy.What role does Etigilimab play i
Myeloid Cell Networks in Cancer Immunotherapy(Post)Understanding Myeloid Cell Networks in Cancer ImmunotherapyImmunotherapy has revolutionized cancer treatment, yet its effectiveness in re-establishing original immune responses post-therapy remains li
Unlocking the Next Wave of Cancer Treatment: The Rise of CAR-T Cell Therapy(Post)A New Era in Oncology Chimeric Antigen Receptor (CAR)-T cell therapy represents a paradigm shift in the fight against cancer, offering a personalized and powerful immunotherapy that trains a patient
TIGIT/DNAM-1/CD155 (PVR) Checkpoint Axis(Page)